Asia Business Gazette
SEE OTHER BRANDS

Fresh news on business and economy in Asia and the Pacific

Asia Business Gazette: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Asia Business Gazette.

Press releases published on May 22, 2025

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

Allogene Therapeutics Announces ASCO 2025 Abstract Publication Featuring Oral Presentation of ALLO-316 in Kidney Cancer and ALPHA3 TIP Poster for Cema-Cel

SOUTH SAN FRANCISCO, Calif., May 22, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer and autoimmune disease, today …

Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th

Daktronics to Participate in the 22nd Annual Craig-Hallum Institutional Investor Conference on May 28th

BROOKINGS, S.D., May 22, 2025 (GLOBE NEWSWIRE) -- Daktronics, Inc. (Nasdaq: DAKT), a leading global designer and manufacturer of best-in-class dynamic video communication displays and control systems for customers worldwide today announced that Brad …

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025

ImCheck Reports High Remission Rates in AML Patients with ICT01 Combination Therapy at ASCO 2025 ICT01 in combination with azacitidine and venetoclax (Aza-Ven) achieves unprecedented high remission rates overall and across molecular subtypes in newly …

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pivotal Phase 2b …

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

Legend Biotech Announces New Oncologic & Hematologic Therapeutic Developments at ASCO, EHA, and ASGCT

An oral presentation at ASCO …

ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity

ROHM Develops Compact Surface-Mount Near-Infrared LEDs Featuring Industry-Leading Radiant Intensity

Santa Clara, CA and Kyoto, Japan, May 22, 2025 (GLOBE NEWSWIRE) -- ROHM Semiconductor today announced an expanded portfolio of surface-mount near-infrared (NIR) LEDs with new compact top-view types optimized for applications such as VR/AR devices, …

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

Menarini Group Presents Updated Data Underscoring the Combinability of Elacestrant (ORSERDU®) in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the ASCO 2025 Annual Meeting

Preliminary efficacy analysis from the elacestrant plus everolimus and ribociclib cohorts of the ELEVATE study, along with updated safety data from additional cohorts of elacestrant plus targeted therapy combination arms, will be presented. These data …

Lynch Carpenter Investigates Claims in Marlboro-Chesterfield Pathology Data Breach

Lynch Carpenter Investigates Claims in Marlboro-Chesterfield Pathology Data Breach

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Marlboro-Chesterfield Pathology (“MCP”) recently announced a cybersecurity incident, which impacted the personal information of thousands of individuals. The information potentially impacted in the data breach …

Lynch Carpenter Investigates Claims in Kettering Health Data Breach

Lynch Carpenter Investigates Claims in Kettering Health Data Breach

PITTSBURGH, May 22, 2025 (GLOBE NEWSWIRE) -- Kettering Health (“Kettering”) recently announced a cybersecurity incident that resulted in the disruption of their network operations across. Details about the approximate number of people affected and the …

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

Boehringer Ingelheim to present early clinical evidence of innate immune modulation and anti-tumor activity via SIRPα blockade in two ongoing trials at ASCO 2025

·        BI 765063 in combination with programmed cell death-1 (PD1) inhibitor antibody ezabenlimab + cetuximab demonstrated a well-tolerated safety profile and potentially promising efficacy signals as second-line treatment in patients with recurrent/ …

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Actuate Therapeutics Announces Details for 2025 ASCO Annual Meeting Presentation on Topline Elraglusib Phase 2 Data in First-Line Treatment of Metastatic Pancreatic Cancer

Phase 2 (Actuate-1801 Part 3B) trial topline results meet primary endpoint of improved survival in previously untreated patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) Oral presentation at the American Society of Clinical Oncology (ASCO) …

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting

CTLA-4 inhibitor ADG126 can be dosed at 20 mg/kg Q6W in combination with pembrolizumab with <20% Grade 3 adverse events In combination with pembrolizumab, ADG126 showed a 29% confirmed overall response rate (ORR) in microsatellite stable colorectal cancer …

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting

Avidicure to Present Preclinical Data from Lead TROP2-targeting Multifunctional Antibody Program at the 2025 American Society of Clinical Oncology Annual Meeting

AMSTERDAM, May 22, 2025 (GLOBE NEWSWIRE) -- Avidicure, a biotechnology company pioneering an entirely new dual agonistic, multifunctional antibody modality with broad applicability in oncology, today announced its upcoming presentation at the 2025 American …

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

NEEDHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, today …

Petrus Announces Results of Annual General Meeting of Shareholders

Petrus Announces Results of Annual General Meeting of Shareholders

CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Petrus Resources Ltd. ("Petrus" or the "Company") (TSX: PRQ) is pleased to announce that its shareholders approved all resolutions at its annual general meeting of shareholders held yesterday (the "Meeting …

Lyme Timber Receives the 2025 SFI Leadership in Conservation Award for Advancing Nature-Based Solutions in SFI-Certified Forests

Lyme Timber Receives the 2025 SFI Leadership in Conservation Award for Advancing Nature-Based Solutions in SFI-Certified Forests

MINNEAPOLIS, May 22, 2025 (GLOBE NEWSWIRE) -- The Sustainable Forestry Initiative (SFI) is pleased to announce The Lyme Timber Company as the recipient of the 2025 SFI Leadership in Conservation Award. Lyme Timber, certified to the SFI Forest Management …

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

Biodesix Announces New Data on the VeriStrat® Test to be Presented at the 2025 ASCO Annual Meeting

LOUISVILLE, Colo., May 22, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, announced today that new data will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, …

Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results

Acceleware Ltd. Reports First Quarter 2025 Financial and Operating Results

CALGARY, Alberta, May 22, 2025 (GLOBE NEWSWIRE) -- Acceleware® Ltd. (“Acceleware” or the “Company”) (TSX-V: AXE), an advanced electromagnetic (“EM”) heating company with highly scalable solutions for large industrial applications, today announced its …

ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis

ImPact Biotech Announces Late-Breaking Podium Presentation at ASCO 2025 Highlighting ENLIGHTED Study Interim Analysis

-- Company to present interim update from ENLIGHTED Phase 3 Study in LG UTUC following assessment of 50% of targeted total evaluable patient enrollment -- TEL AVIV, Israel, May 22, 2025 (GLOBE NEWSWIRE) -- ImPact Biotech, a clinical-stage biotechnology …

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

Partner presentations reinforce ability of proprietary Azymetric™ platform to develop clinically validated therapeutic antibodies Long-term outcomes and survival data for Ziihera® (zanidatamab-hrii), which was developed using Azymetric™, to be presented at …

Share us

on your social networks:
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms of Service